Table 1.
Patients characteristics after propensity-score matching.
| Variables | SEED-BT alone (n = 102) | SEED-BT plus EBRT (n = 102) | P |
|---|---|---|---|
| Age at radiotherapy, median (range), years | 69 (50–81) | 71 (49–79) | 0.359 |
| PSA at diagnosis, median (range), ng/mL | 8.5 (2.6–16.7) | 8.3(4.1–18.8) | 0.902 |
| Clinical stage, number (%) | 0.322 | ||
| T1c | 55 (53.9) | 62 (58.8) | |
| T2a-c | 47 (46.1) | 40 (41.2) | |
| Gleason grade, number (%) | 0.809 | ||
| 1 | 17 (16.7) | 19 (18.6) | |
| 2 | 31 (30.4) | 27 (26.5) | |
| 3 | 54 (52.9) | 56 (54.9%) | |
| Positive biopsy core rate, number (%) | 0.640 | ||
| < 34% | 57 (55.9) | 60 (58.8) | |
| 34–67% | 42 (41.2) | 37 (36.3) | |
| > 67% | 3 (2.9) | 5 (4.9) | |
| Unfavorable intermediate risk, number (%) | 75 (73.5) | 79(77.4) | 0.515 |
| Neoadjuvant hormonal therapy yes, number (%) | 24 (23.5) | 24 (23.5) | 1.000 |
| Anti-androgen agent alone, number | 1 | 7 | |
| Anti-androgen agent with GnRHa, number | 20 | 17 | |
| GnRHa alone, number | 3 | 0 | |
| Adjuvant hormonal therapy yes, number (%) | 0 (0) | 0 (0) | – |
| Follow-up, median (range), months | 97 (22–153) | 90 (18–153) | 0.046 |
| BED, median (range), Gy2 | 200.0 (138.3–281.3) | 217.1 (192.2–284.1) | < 0.001 |
| BED ≥ 200 Gy2, number (%) | 51 (50.0) | 96 (94.1) | < 0.001 |
| Prostate D90, median (range), Gy | 187.7 (132.2–258.4) | 124.7 (97.0–180.8) | < .0001 |
| Prostate V100, median (range), % | 98.9 (84.7–100) | 96.7 (87.7–99.6) | < 0.001 |
| Prostate V150, median (range), % | 70.7 (40.1–97.2) | 64.9 (39.2–87.5) | < 0.001 |
Prostate D90 indicates minimal dose received by 90% of prostate gland at 1 month on SEED-BT. Prostate V100 and V150 indicates percentage of prostate gland volume receiving 100% and 150% of the prescribed dose, respectively, at 1 month on SEED-BT.
BED, biochemical effective dose; EBRT, external beam radiotherapy; GnRHa, gonadotropin-releasing hormone agonist; PSA, prostate specific antigen; SEED-BT, seed brachytherapy.